Clinical Research

Clinicopathologic Pattern and Outcome of Management of Pancreatic Carcinoma in Ibadan, Nigeria

B. J. Alegbeleye¹, Adefemi O. Afolabi², and Bamidele Johnson Alegbeleye¹

¹Department of Surgery, Banso Baptist Hospital, Northwest Region, Cameroon
²Department of Surgery, University College Hospital, Ibadan, Nigeria

Abstract

Background: Pancreatic cancer is one of the most challenging tumor entities worldwide, characterized as a highly aggressive disease with dismal overall prognosis and an incidence rate equaling mortality rate.

Objective: In order to have an up-to-date data on pancreatic cancer incidence and trend in Nigeria, West Africa, we conducted an epidemiological analytical review of the pattern, management, and management outcome of pancreatic cancer in Ibadan, Nigeria.

Methods: We performed a retrospective hospital-based study in which we analyzed the records of 126 pancreatic cancer patients registered, evaluated, and treated in the University College Hospital, Ibadan, a major referral tertiary Hospital in the south western region of Nigeria, West Africa from January 1999 to January 2013.The data obtained include bio-data, clinical presentation, treatment and outcome that were analyzed with descriptive statistics using SPSS 22.

Results: During the period of study, 126 patients were diagnosed with pancreatic cancer, with a mean age of 60.2 years and a male-to-female ratio of 1.52:1; other parameters such as a medical history of smoking and alcoholism, tumor site, histological type, as well as the stage of diagnosis were also considered at the time of the enrolment in the study. Our statistical analyses reported a very significant correlation between patients who belonged to the age group of 30–45 years and the advanced stage of diagnosis (based on TNM classification) with \( P = 0.02 \).

Conclusion: Pancreatic cancer is increasingly diagnosed in young adults at an advanced stage in the West African sub-region. Most patients present with advanced condition only amenable to palliative measures. There are significant challenges in the area of diagnosis, screening, treatment and research. The role of public health campaign to educate the populace on the disease and early presentation cannot be overemphasized.

Keywords: pancreatic cancer, clinicopathologic pattern, Ibadan-Nigeria
1. Introduction

Pancreatic cancer is one of the most challenging tumor entities worldwide, characterized as a highly aggressive disease with dismal overall prognosis and an incidence rate equaling mortality rate [1, 2]. Less developed regions have low rates of pancreatic cancer [2], and it is relatively rare in Africa and Asia [3, 4]. However, despite all the efforts in the medical research of the disease, it ranks as the fourth deadliest cancer in the United States after the cancers of the lung, colon, and breast. The Cancer Registry at the University College Hospital (UCH), Ibadan, indicates that it trails behind primary carcinoma of the liver, carcinoma of the stomach, and carcinoma of the colon among gastrointestinal tumors [5]. The incidence rate in the UCH, Ibadan, is 3.8% [5].

In 2013, an estimated 45,220 newly diagnosed cases of pancreatic cancer and 38,460 deaths were expected in the United States [6]. The main reason could be the difficulty of its diagnosis since no specific cost-effective screening tests can easily and reliably find early stage pancreatic cancer in people who have no symptoms of the disease. This means it is often not found until later stages when the cancer can no longer be removed with surgery and has spread from the pancreas to other parts of the body [7]. In fact, the Surveillance, Epidemiology, and End Results (SEER) database also shows that for every 12.2 patients diagnosed per 100,000, 10.9 will die from pancreatic cancer, despite the best efforts of researchers and clinicians to improve survival outcomes in patients [8]. The overall five-year survival rate is less than 5% [9–11]. The peak incidence of pancreatic carcinoma occurs in the seventh decade [12]. There are variations in incidence in different populations ranging from 2.2 new cases per 100,000 populations in India, Kuwait, and Singapore to 12.5/100,000 in Sweden [12, 13]. The incidence in most developed countries is similar to that of the United States [13]. Most research on pancreatic cancer has come from developed countries. Some of these researches have indicted some environmental factors in the occurrence of this disease [14, 15]. The environmental factors include cigarette smoking, alcohol consumption, high meat intake, and occupational exposure to carcinogen like Dichlorodiphenyltrichloroethane (DDT) and other organochlorine pesticides. Most of these environmental factors are very prevalent in Africa, especially Nigeria - the world’s largest nation of people of color. Study from Egypt showed that the incidence of pancreatic cancer is higher in the area of the country where this environmental factor abound [16, 17]. Numerous reports have been published by Western countries on this disease entity but only few works have been done on this area of interest in Nigeria and Africa in general [5, 8–12, 18–24]. The need to look at local data also becomes very imperative because of the findings of few
studies that show that African American and economic disadvantage population have higher incidence of pancreatic cancer [12–14, 18–26].

This study aimed to bring to the fore the hospital incidence, sociodemographic characteristics and management’s outcome of carcinoma of pancreas at the UCH, Ibadan, Nigeria. We also discuss the challenges associated with the management of the disease in low-resource settings like ours that are typical of the health sector in the sub-Saharan African region.

2. Methods

The study was conducted at the UCH, Ibadan, Nigeria, from January 1999 to January 2013. The hospital is the largest hospital in the south of Sahara and provides services to both the rural and urban communities in the southwestern Nigeria. The hospital also serves as the referral tertiary hospital for an estimated population of approximately 20 million people in the southwestern states of Nigeria and neighboring West African countries.

2.1. Data collection

This was a retrospective cohort study of all patients managed for pancreatic cancer in the surgical wards of the UCH, Ibadan, Nigeria, between January 1999 and January 2013. The admission and discharge diagnosis and procedure codes as well as the Cancer Registry database were obtained from the Central Record of the hospital. The Current Procedural Terminology (CPT) and the International Classification of Diseases Ten Revision (ICD-10) codes for “Triple bypass,” “pancreaticoduodenectomy,” and “pancreatic cancer” were used to identify patients with proven or suspected pancreas neoplasm undergoing surgery. Manual review of patient records was performed to obtain relevant data points. The data collected include the sociodemographics, laboratory parameters, the treatment modalities, as well as the outcome of management.

The diagnosis of pancreatic cancer was made using the combination of clinical parameters, upper gastrointestinal endoscopy, and radiological findings. Clinical parameters used included jaundice, upper abdominal mass, upper abdominal pain that radiate to the back, weight loss, and palpable gall bladder. Radiological parameters included ultrasound and/or Computerized Tomography (CT) scan showing pancreatic mass. Upper gastrointestinal endoscopy was done for most of the patients to rule out the possibility of gastric cancer. Endoscopic retrograde cholangiopancreatography was not done.
for any of the patients because the facility was not available. All the patients with conflicting findings which could not be substantiated at surgery were excluded from the study. Histopathological finding further corroborated the diagnoses for patients that had surgery or during the postmortem examination. Sixteen (12.7%) patients did not have histopathology result.

All the data obtained were coded, edited appropriately, and entered into personal computer. The data were analyzed using the Statistical Packaging for Social Sciences (SPSS; IBM Corporation; Chicago, IL, USA. August 2011) version 22.0. Simple descriptive statistics were used. Median and frequencies were calculated based on the numerous data points. The \( P \)-values were provided to indicate statistical significance. \( P < 0.05 \) was regarded as significant. Chi-square tests were used to compare categorical variables such as sex. Fisher exact test was used where applicable. Student \( t \)-test was used to compare mean age between the groups.

### 3. Results

The study population was 126 patients diagnosed with cancer of the pancreas but only 82 patients had histological proof of pancreatic cancer. This accounted for 3.1% of all malignancies seen and 358/100000 total admissions during the study period. The median age was 60.2 years with male-to-female ratio of 1.52.

As seen in Table 1, the most common age group affected with pancreatic cancer is age group 51–60. There were 76 (60%) male and 50 (40%) female with male-to-female ratio being 1.52:1. Majority of the patients were artisans (39.8%) and farmers (26.4%). Other patients were either traders or professionals.

The duration of symptoms ranged from 6 weeks to 125 weeks with a median of 25 weeks. None of our patients had a family history of pancreatic cancer. Only 25 (20%) patients had a previous history of diabetic mellitus (DM) before the onset of the symptoms. The diagnosis of DM was made within one year prior to the commencement of the symptoms in all 25 patients; 12 and 15 patients had significant history of cigarette smoking and alcohol intake, respectively. On investigation, 94% of the patients had elevation of alkaline phosphatase, 40% had elevated aspartate transaminase, 96% had elevated bilirubin, and 70% had packed cell volume of less than 28 at the time of presentation.

Only 12 (11%) patients had tumor located in a specified anatomical sub site: 10 in the head of pancreas and 2 in the tail of the pancreas. Other patients had extensive tumor
Table 1: Patients' medical features.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No. of Cases</th>
<th>Percentage %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex (N = 126)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>76</td>
<td>60</td>
</tr>
<tr>
<td>Female</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td><strong>Sex ratio</strong></td>
<td></td>
<td>1.52</td>
</tr>
<tr>
<td><strong>Age (Years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 20</td>
<td>1</td>
<td>0.8</td>
</tr>
<tr>
<td>21–30</td>
<td>12</td>
<td>9.2</td>
</tr>
<tr>
<td>31–40</td>
<td>30</td>
<td>24</td>
</tr>
<tr>
<td>41–50</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td>51–60</td>
<td>25</td>
<td>19.8</td>
</tr>
<tr>
<td>61–70</td>
<td>31</td>
<td>25</td>
</tr>
<tr>
<td>&gt; 70</td>
<td>9</td>
<td>7.2</td>
</tr>
<tr>
<td><strong>Alcohol</strong></td>
<td>31</td>
<td>24.3</td>
</tr>
<tr>
<td><strong>Smokers</strong></td>
<td>38</td>
<td>30.2</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jaundice</td>
<td>118</td>
<td>94</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>120</td>
<td>95</td>
</tr>
<tr>
<td>Right hypochondrial pain</td>
<td>113</td>
<td>90</td>
</tr>
<tr>
<td>Nausea &amp; vomiting</td>
<td>111</td>
<td>88</td>
</tr>
<tr>
<td>Weight loss</td>
<td>107</td>
<td>85</td>
</tr>
<tr>
<td>Dark urine</td>
<td>88</td>
<td>70</td>
</tr>
<tr>
<td>Pruritus</td>
<td>82</td>
<td>65</td>
</tr>
<tr>
<td><strong>Tumor Site</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Head of the Pancreas</td>
<td>113</td>
<td>90</td>
</tr>
<tr>
<td>Body of the Pancreas</td>
<td>8</td>
<td>6.2</td>
</tr>
<tr>
<td>Tail of the Pancreas</td>
<td>5</td>
<td>3.8</td>
</tr>
</tbody>
</table>

Involving the head and body of the pancreas. There were liver metastases in 32 (29.1%) patients at the time of presentation.

Of the 98 (78%) patients who had surgery, 71 (56%) had triple bypass and 27 (22%) had a double bypass procedure. Two patients with localized tumor of the head of pancreas had pancreaticoduodenectomy. The two patients with tumor at the pancreatic tail had resection of the tumor and splenectomy. Eighty-six (88%) of the operated patients had locally advanced pancreatic mass. These patients had triple bypass to relieve the obstructive jaundice. Ten patients had biopsy alone of the pancreatic mass or the lymph node because of the widespread metastasis to the bowel, liver, and other organs in the peritoneal cavity. Twenty-eight patients had adjuvant chemotherapy. Agents used include 5-fluorouracil and Adramycin.
The two patients who had pancreaticoduodenectomy were lost to follow-up after a year. No recurrence was recorded for the patient with tumor at the tail of pancreas after five years of follow-up. Median survival for patients that had triple bypass was eight months. This was statistically significant ($p = 0.02$). Within three months of presentation, 42 (33.3%) patients with pancreatic cancer died. As shown in Table 2, the factors that were found to be significant in patients that died within three month of presentation include elevated transaminases, low serum protein and bicarbonate. Table 3 shows the various complications from bypass surgery. The most common complication of triple bypass is bile leak which was seen in two patients.

**Table 2:** Factors affecting the outcome of management of patients with pancreatic cancer.

<table>
<thead>
<tr>
<th>Factors</th>
<th>Degree of Freedom</th>
<th>P-Value</th>
<th>95% Confident Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>94</td>
<td>0.245</td>
<td>3.122–6.880</td>
</tr>
<tr>
<td>Sex</td>
<td>1</td>
<td>0.045</td>
<td></td>
</tr>
<tr>
<td>Duration of Symptoms before presentation</td>
<td>94</td>
<td>0.624</td>
<td>–12.431–5.765</td>
</tr>
<tr>
<td>Serum Bilirubin</td>
<td>94</td>
<td>0.442</td>
<td>–33.854–78.623</td>
</tr>
<tr>
<td>ALT</td>
<td>94</td>
<td>0.004</td>
<td>12.254–66.732</td>
</tr>
<tr>
<td>AST</td>
<td>93</td>
<td>0.0002</td>
<td>11.684–49.271</td>
</tr>
<tr>
<td>Alkaline Phosphate</td>
<td>94</td>
<td>0.932</td>
<td>–354.821–197.472</td>
</tr>
<tr>
<td>Total Serum Protein</td>
<td>94</td>
<td>0.054</td>
<td>–11.641–782</td>
</tr>
<tr>
<td>Serum Potassium</td>
<td>94</td>
<td>0.851</td>
<td>–3446–2378</td>
</tr>
<tr>
<td>Serum Sodium</td>
<td>94</td>
<td>0.444</td>
<td>–6.576–4123</td>
</tr>
<tr>
<td>Serum Creatinine</td>
<td>94</td>
<td>0.234</td>
<td>–22.678–54.544</td>
</tr>
<tr>
<td>Serum Bicarbonate</td>
<td>94</td>
<td>0.022</td>
<td>–5.777–3240</td>
</tr>
<tr>
<td>PT</td>
<td>94</td>
<td>0.044</td>
<td>–2.789–1.233</td>
</tr>
<tr>
<td>INR</td>
<td>32</td>
<td>0.232</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3:** Complications associated with methods of triple bypass.

<table>
<thead>
<tr>
<th>Complications</th>
<th>Braun Method</th>
<th>Roux-en-Y Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bile leak</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Recurrent vomiting</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Prolonged ileus</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Wound infection</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>10</td>
<td>3</td>
</tr>
</tbody>
</table>

**4. Discussion**

All around the globe, significant progress are being made to better understand the molecular biology of pancreatic cancer which has not significantly impacted on the
outcome of management. This is because such concerted past efforts, on the conventional treatment approaches, such as surgery, radiation, chemotherapy, or combinations have yielded very little results. Pancreatic tumors remain deadly and rarely curable [25, 27–29]. In this study, we found that the hospital incidence of pancreatic cancer is 358 per 100,000 hospital admissions that accounts for 3.1% of all cancer cases seen in our center. For several decades, the incidence of pancreatic cancer has been consistently higher in the people of color than in the whites in the United States [27, 28, 30].

The present survey is one of the very few surveys that studied the profile of pancreatic cancer in West Africa in general and Nigeria in particular.

With a sex ratio of 1.52, our investigation confirmed once more that men are more likely to develop pancreatic cancer than women. These results matched with many other previous investigations as those of Schiffman et al. [18, 19, 31].

Our results showed that 28% of our patients were cigarette smokers and 22% were alcoholics. This could represent a risk factor for developing a pancreatic cancer since several published reports showed that smokers had about a twofold increased risk compared to nonsmokers [32, 33].

We noticed also that most of our patients complained of jaundice; right hypochondrial pain and abdominal pain; which proves that pancreatic cancer is a silent disease, as reported in many other findings that stated that pancreatic cancer symptoms do not manifest early and initial symptoms are often nonspecific [18, 19, 34]. Concerning tumors’ location, most of them were located in the head of the pancreas (90%), followed respectively by cancer of the neck and the tail of the pancreas that represented a tiny minority. The study of Kalser et al. demonstrated as well that more than two-thirds of pancreatic cancers occur in the head of the pancreas [18, 35].

Diabetes mellitus was associated and pointed in several investigations as possible risk factor for pancreatic cancer [18, 33] in concordance with our findings, since 25% of our studied population presented with type 1 and type 2 of diabetes.

Our survey also demonstrated an increasing frequency of pancreatic cancer with the advanced age of patients since most of them were aged between 60 and 80 years old, these results agree with those of Shibata’s et al. who concluded that this could be due to the dietary habits of the patients [18, 19, 36].

On the other hand, the current investigation confirmed indeed the rarity of pancreatic cancer in young adults; since only 8% of our population suffered from it, which agrees with the results of Perez et al. who found that the incidence of identified pancreatic carcinomas in patients under the age of 30 was only about 0.46/million [37]. The conclusion for Lüttges et al. was the same, where the incidence of pancreatic ductal
adenocarcinomas in patients aged 40 years was approximately equal to 0.3% and the incidence in patients aged 20 years was only about 0.1% [38].

However, despite the low rate of our patients (8%) belonging to that young age group, 35% of them were diagnosed at M1 stage that represented the majority.

Concordant with our results and those of Brand et al. who found that pancreatic cancer is increasingly diagnosed among young patients at an advanced stage [39], Berry et al. stated that nearly 50% of patients aged between 16 and 54 with pancreatic cancer are more likely than those who are older to be diagnosed at a stage when the disease is incurable, because of poor awareness, misdiagnosis, and care delays [18, 19, 40].

Some authors confirm that pancreatic cancer is frequently diagnosed at an advanced stage, possibly because of the tumor biology showing an aggressive behavior and symptoms, often being non-specific and mainly among the young ones [41]; Gulliford et al. reported as well that patients with some less common cancers such as pancreatic cancer were more likely to require three visits or more to their primary care physician before they were referred to a specialist [42]. What we have to emphasis as well is the status of Nigeria as a developing country, thus it’s undeniable that inadequate healthcare facilities, high-priced drugs, lack of cancer diagnostic and therapeutic kits, insufficient medical check-ups, as well as the low socioeconomic level of Nigerian citizen are all major factors that may have a direct impact on the survival chances of this fatal disease.

Since most of our patients had pancreatic adenocarcinomas (Table 2) presented in late stage at the time of diagnosis, their prognosis was very poor – with a one-year survival rate of 20% and a five-year survival rate of less than 5% – similar to the survey of Kuvshinoff et al. [43]. The only hope of long-term survival is if curative resection can be undertaken; however, since pancreatic cancer patients seldom exhibit disease-specific symptoms until late in the course of the disease, very few patients (< 15–20%) have resectable disease by the time the diagnosis is made [18, 19, 44, 45]. While complete surgical resection may lead to long-term survival in approximately 25% of patients, only 15% are actually resectable [43]. It is therefore essential to distinguish all kinds of tumor from other pancreatic neoplasms particularly adenocarcinoma for which the prognosis is extremely poor as stated earlier [46]. Surgery for pancreatic cancer is probably the most demanding and risky operative procedure in abdominal surgery [47]. Nevertheless, the huge lack of diagnostic facilities and cancer research centers in Nigeria and other developing countries have a major negative impact on the precision and quality of the diagnosis.
Seelig et al. reported that in a young patient with advanced disease, resection may give a weak but valuable increased survival. In fact, metastatic pancreatic cancer could become overt when the point of no return has already been reached as it could be the case in the presence of positive interaortocaval lymph nodes, or metastatic cancer will be detected during operation despite negative imaging results preoperatively [48]. Picozzi et al. affirmed that despite R0 resection, long-term survival does not exceed 25% even in the most experienced pancreatic centers and may prove that carcinoma of the pancreas is a systemic disease [49]. At presentation, most of our patients had advanced disease. Resection rate was about 3% which is very low compared with the data from developed country where resection rate of as high as 15–20% has been quoted [14]. The stage of the tumor has been found to be an important predictor of resectability and death in patients with pancreatic tumor [50]. This is because of the location of pancreas; early symptoms of pancreatic cancer are so vague and are usually ignored by most patient. Presentation with advanced stage of the disease may also be due to poor health-seeking behavior of our patients [18, 19, 51, 52]. Obviously, a high index of suspicion on the part of health workers is essential for early detection of pancreatic cancer. Another reason for late presentation in our patients may be due to aggressive growth behavior of the pancreatic cancer that leads to early dissemination of the tumor [14, 53]. Various efforts have been made on how to diagnose pancreatic cancer early with little success [54, 55]. Presently, no population screening modality is available for pancreatic cancer. Moreover, targeted screening is also very difficult for pancreatic cancer because primary causal factors for this tumor are poorly understood. While effort is been made along this line, it is worthy to note that endoscopic ultrasonography has been shown to be a reliable way to detect tumor invasion of visceral vessels and thus predict unresectability. It also has the potential to be used to diagnose pancreatic cancer early [18, 19, 55, 56].

In Solanke et al. [20] series, pancreatico-duodenectomy was performed on only 3 out of 47 patients; 2 with carcinoma of head of pancreas and 1 with disease of the ampulla of Vater. One died after two months, another after five months, and the third with ampullary carcinoma was alive and well after ten months. Palliative procedures were carried out on 14 patients and laparotomy alone was performed on 11 patients. The one-year survival rate of 2% was reported by Solanke et al., which was similar to this study [20]. Only 6 out of the 36 patients of Ajao et al. [21] had exploratory laparotomy; none had resectable disease. In Lagos, 10 out of the 20 patients encountered by Olumide et al. [22] had laparotomy; none was resectable and 7 had palliative operations consisting of bypass procedures.
Further improvement of survival can only be achieved by adjuvant treatment [49].

The need for adjuvant therapy in pancreatic cancer cannot be over emphasized. Even with complete surgical resection, most patients will die of recurrent disease because of the multifocality of the disease and micrometastasis [57, 58]. Several studies have shown that the outcome of patients are improved when placed on adjuvant chemotherapy, radiotherapy, or a combination of the two [14, 18, 19, 58, 59]. Pancreatic cancer is moderately sensitive to few agents like gemcitabine, capecitabine, cisplatin, bevacizumab, and cetuximab [15, 18, 19, 60]. Most of these agents are more toxic, rarely available in our environment or very expensive. One important question that is yet to find an answer is the reason why pancreatic cancer is resistance to most commonly available chemotherapy. Radiotherapy facilities are extremely congested; hence, the facilities are made available to those that will benefit most from the facilities and the privileged few. This makes the management of patients with pancreatic cancer very difficult.

Our survey clearly showed that young adults who suffered from pancreatic cancer in general and cancer of the head of pancreas in particular are unfortunately diagnosed at a very late stage in South Western Nigeria, when the likelihood of recovery is poor and patients have no other choice than to accept their ongoing symptoms.

Furthermore, we found that patients with elevated transaminases, low serum sodium, and reduced total protein indicate that patients had very advanced disease with a much reduced life expectancy. These may be due to the involvement of the liver in this condition. These simple parameters can help predict a poorer outcome at presentation. Further study will be needed to substantiate this finding. For a long time, pancreatic cancer has been regarded as terminal disease (“captain of death”); hence little attention is given to the research on the disease. Report on pancreatic cancer is extremely scarce in Nigeria or Africa. There is a great need therefore for concerted effort to characterize pancreatic cancer in Nigeria.

5. Conclusion

The incidence of pancreatic cancer is relatively low in our center. Most patients present with advanced condition only amenable to palliative measures. Young adult patients are often seen to be healthier than older ones. Lack of awareness, socio-cultural habits, and carelessness could be fatal for patients who suffer from pancreatic cancer; therefore, awareness should be increased among healthcare professionals and mainly among Third World countries’ citizen. The earlier the diagnosis is made, the better are the
chances for the patient’s survival. There are still significant challenges in the area of diagnosis, screening, treatment, and research. The role of public health campaign to educate the populace on the disease and early presentation cannot be overemphasized.

Ethical Approval

NOT APPLICABLE/WAIVED – The Institutional Ethical Approval was not required for Retrospective Review of Data within the UCH - Cancer Registry as long as the data were used for Studies or Research by the Attending Surgeons of the Department.

Consent for Publication

NOT APPLICABLE/WAIVED – This is a retrospective study, therefore there is no direct human participants involvement.

Conflict of Interest

The authors declare that they have no conflict of interest.

Acknowledgment(S)

None

Authors’ Contributions

All authors contributed equally in the study and participated in its design and coordination and helped to draft the manuscript. They also read and approved the final manuscript.

References


WHOdb.htm


